Table 1 Overview of female adverse event reports submitted for statins in FAERS.
Counting numbers by age groups (years) | Statins as a class | Atorvastatin | Simvastatin | Rosuvastatin | Pravastatin | Lovastatin | Fluvastatin | Pitavastatin |
|---|---|---|---|---|---|---|---|---|
Number of AE reports (n, %) | ||||||||
 Overall | 151,924 | 64,177 | 44,586 | 28,991 | 10,810 | 4,965 | 1,591 | 916 |
 0–18 | 279 (0.18%) | 102 (0.16%) | 74 (0.17%) | 39 (0.13%) | 30 (0.28%) | 25 (0.50%) | 5 (0.31%) | 2 (0.22%) |
 19–39 | 2,663 (1.75%) | 1,034 (1.61%) | 915 (2.05%) | 416 (1.43%) | 197 (1.82%) | 87 (1.75%) | 48 (3.02%) | 10 (1.09%) |
40–59 | 30,198 (19.88%) | 12,287 (19.15%) | 9,150 (20.52%) | 6,049 (20.87%) | 2096 (19.39%) | 1,082 (21.79%) | 372 (23.38%) | 167 (18.23%) |
 ≥ 60 | 73,777 (48.56%) | 30,003 (46.75%) | 22,203 (49.80%) | 14,032 (48.40%) | 5,618 (51.97%) | 2,344 (47.21%) | 800 (50.28%) | 528 (57.64%) |
Number of ovary and uterus related PTs with positive signals (n) | ||||||||
 Overall | 2 | 6 | 9 | 2 | 3 | 2 | 5 | 0 |
 0–18 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
 19–39 | 3 | 1 | 2 | 1 | 1 | 0 | 0 | 0 |
 40–59 | 6 | 5 | 9 | 2 | 2 | 4 | 2 | 0 |
 ≥ 60 | 6 | 5 | 8 | 0 | 1 | 1 | 3 | 0 |
 Total number | 15 | 12 | 19 | 3 | 6 | 5 | 5 | 0 |
